Improving Therapeutic Efficacy For Brain-Based Cancers Using NEO 100
NEO 100 Enables Brain Delivery Of Blood-Brain Barrier-Impermeable Therapeutics.
Authors: Weijun Wang 1, Nagore I. Marín-Ramos1, Haiping He1,2, Shan Zeng1,2, Hee-Yeon Cho1, Stephen D. Swenson1, Long Zheng3, Alan L. Epstein3, Axel H. Schönthal4, Florence M. Hofman3, Ligang Chen2, and Thomas C. Chen1,4
NeOnc Technologies conducted a study of its NEO 100 Perillyl Alcohol (POH) formulation to determine its in vitro Blood-Brain Barrier (BBB) permeability using transepithelial/transendothelial electrical resistance (TEER) and antibody diffusion
assays. Ultrasound-guided intracardiac administration of NEO100, followed by intravenous application of Evan’s blue, methotrexate, checkpoint-inhibitory antibodies, or CAR T-cells was conducted on mouse models.
The study showed that NEO 100 opened the BBB in a reversible and non-toxic fashion in vitro and in vivo. It enabled greatly increased brain entry of all tested therapeutics and was well tolerated by animals. Mechanistic studies revealed the effects of NEO 100 on different BBB transport pathways, along with translocation of tight junction proteins from the membrane to the cytoplasm in brain endothelial cells.
Hospital of Southwest Medical University, Luzhou 646000, China, 3Department of
Pathology, Keck School of Medicine, The University of Southern California (USC), Los Angeles, CA 90033, USA, 4Department of Microbiology and Immunology, Keck School of Medicine, The University of Southern California (USC), Los Angeles, CA 90033, USA